Court Orders, Stock Price Movements, FDA Approvals and Strategic
Collaborations - Research Report on Johnson & Johnson, Santarus, Salix, St.
Jude Medical, and Covance
NEW YORK, November 21, 2013
NEW YORK, November 21, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Johnson &
Johnson (NYSE: JNJ), Santarus, Inc. (NASDAQ: SNTS), Salix Pharmaceuticals,
Ltd. (NASDAQ: SLXP), St. Jude Medical, Inc. (NYSE: STJ) and Covance Inc.
(NYSE: CVD). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
Johnson & Johnson Research Report
On November 19, 2013, Bloomberg reported that Janssen Pharmaceuticals
(Janssen), a unit of Johnson & Johnson family of Companies (Johnson &
Johnson), was ordered by a Philadelphia jury to pay $11 million in a case
claiming that the Company's anti-seizure drug Topamax caused birth defects.
According to the Bloomberg report, jurors in state court in Philadelphia found
that Janssen Pharmaceuticals failed to adequately warn doctors for Haley
Powell, a stay-at-home mother, of the risks of Topamax before she gave birth
to a son with a cleft lip. The Bloomberg report added that Janssen lost a
c.$4.0 million verdict on October 30, 2013 in a lawsuit brought by Virginia
resident April Czimmer for injuries to her six-year-old son. Bloomberg
reported that Janssen will appeal the verdicts in both cases. The Full
Research Report on Johnson & Johnson - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
Santarus, Inc. Research Report
On November 18, 2013, Santarus, Inc.'s (Santarus) stock rose 0.06%, ending the
day at $32.12. Over the previous three trading sessions, shares of Santarus
gained 0.47%, compared to the Nasdaq Composite which declined 0.42% during the
same period. The Full Research Report on Santarus, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
Salix Pharmaceuticals, Ltd. Research Report
On November 18, 2013, Salix Pharmaceuticals, Ltd. (Salix) announced that the
Center for Devices and Radiological Health (CDRH) of the Food and Drug
Administration (FDA) has approved Deflux premarket approval (PMA) supplement,
which requested approval of labeling changes to add two additional techniques
for injection, a single intra-ureteric injection (HIT procedure) and a double
(proximal and distal) intra-ureteric injection (Double-HIT procedure).
According to the Company, the Double-HIT procedure is a refinement of the
original STING and HIT procedures and has been reported to result in greater
clinical success rates. Carolyn Logan, President and CEO of Salix said,
"Deflux® has always been an effective, minimally invasive option for children
suffering from vesicoureteral reflux grades II-IV. This approval and update to
the Deflux® labeling provides pediatric urologists even more confidence to
offer Deflux to families." The Full Research Report on Salix Pharmaceuticals,
Ltd. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
St. Jude Medical, Inc. Research Report
On November 18, 2013, St. Jude Medical, Inc.'s (St. Jude Medical) stock
declined 0.98%, ending the day at $56.81. Over the previous three trading
sessions, shares of St. Jude Medical declined 1.47% compared to the S&P 500
which gained 0.53% during the same period. The Full Research Report on St.
Jude Medical, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
Covance Inc. Research Report
On November 18, 2013, Covance Inc. (Covance) and NeoGenomics Inc.
(NeoGenomics) announced a strategic collaboration to jointly provide anatomic
pathology and specialty laboratory testing services for global clinical
trials. Covance stated that through this alliance, its clients will gain
access to fully integrated anatomic pathology and histology (APH) services,
including immunohistochemistry (IHC), fluorescence in-situ hybridization
(FISH), and molecular testing. The Company stated that as part of the
alliance, Covance will have access to NeoGenomics' extensive medical and
scientific networks while NeoGenomics gains access to Covance's broad market
reach, established client relationships, and extensive clinical trials
experience. Covance added that it will develop a laboratory at NeoGenomics'
Fort Myers, Florida facility and will provide a full range of APH,
tissue-based biomarkers and other specialty testing services. Paul
Kirchgraber, M.D., Vice President of Laboratory Operations & Medical Affairs,
Covance Central Laboratory Services, said, "The collaboration with NeoGenomics
will offer our clients fully integrated anatomic pathology services from
sample preparation, staining and imaging, to pathology interpretation by
leading pathologists, in an end-to-end manner." According to Covance, the
companies will expand joint capabilities globally at Covance's central
laboratory locations in Shanghai, China; Geneva, Switzerland; and Singapore.
The Full Research Report on Covance Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
are only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE Analysts' Corner
Contact: Media Contact: Joe Thomas; +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.